Novart confirms The long-term efficacy and safety of Emwave

new data from Novarma confirm the long-term efficacy and safety of erenumab for most people with seizure migraines.
The pharmaceutical giant announced the results of a five-year open-label treatment that examined the drug's continued efficacy and long-term safety and found that 77 percent of patients had reduced their monthly migraine days (MMD) by at least 50 percent after 4.5 years, 33 percent of patients who continued treatment had achieved a 100 percent reduction, and 56 percent had achieved a 75 percent reduction in MMD.
These additional long-term data complement Amway's position as the most prescribed anti-CGRP drug, with more than 250,000 patients worldwide receiving prescriptions since its launch.
According to Estelle West-Brolan, head of global neuroscience medicine, the company said it was "delighted to see that during OLTP, Amway not only reduced the number of migraine days per month, but also the number of days required for acute migraine-specific medications," adding that "these 4.5 years of data further add to the established benefits of Amway for migraine sufferers." Novaral is committed to reimagining migraine treatment to provide patients with effective preventive treatment options to recover from this extremely weak disease. As
, the Scottish Medicines Union (SMC) accepted the drug for patients with chronic migraines, with at least three other preventive drugs not used successfully.Earlier this year, Ammerway also caused a stir when Amway and Novarma sued each other in federal court over Novarma's decision to sign a production contract with Alder Biopharmaceuticals, which is developing Amway's potential rival. (cyy123.com)